Objective: Matrilin-3 is a member of the recently described matrilin family of extracellular matrix proteins containing von Willebrand factor A-like domains. The matrilin-3 subunit can form homo-tetramers as well as hetero-oligomers together with subunits of matrilin-1 (cartilage matrix protein). It has a restricted tissue distribution and is strongly expressed in growing skeletal tissues. Detailed information on expression and distribution of extracellular matrix proteins is important to understand cartilage function in health and in disease like osteoarthritis (OA).
Introduction
Osteoarthritis (OA) is a degenerative joint disease, involving mechanical, biochemical, hormonal, and genetic factors. The relative importance of these factors varies in the disease process and cannot be defined easily in patients with OA. The continuous loss of the articular cartilage matrix is the prominent feature of the progressive osteoarthritic process. The cartilage of articular joints is an extremely specialized tissue which enables a stable and smooth movement of the joint surfaces and, equally important, the dissipation of mechanical load under physiological conditions. Type II collagen and aggrecan, the two most abundant components of the cartilage extracellular matrix, are major contributors to these properties and have, therefore, been analysed extensively 1, 2 . Cartilage collagen fibrils form highly organized three-dimensional structures responsible for the tissue stiffness. Under-hydrated proteoglycans within this meshwork contribute to the compensation of the load stress and are mainly responsible for the visco-elastic properties of the articular cartilage matrix. Additional components of the extracellular matrix such as type VI collagen, are implicated as being important in the mechano-protective filament structures that surround the chondrocytes 3 . Other cartilage proteins and proteoglycans such as COMP, CILP, fibronectin, and decorin have putative functions in cell-matrix and matrix-matrix interactions (reviewed in Neame et al. 4 ). Matrilin-3 belongs to a family of extracellular matrix proteins with members that share similarities in their modular compositions (reviewed in Deák et al. 5 ). Matrilin-1 (earlier called cartilage matrix protein or CMP), -2, -3, and -4 share an N-terminal signal peptide domain, often followed by a short stretch of positively charged amino acids and a von Willebrand factor A (vWFA)-like domain. Close to the vWFA-like domain, one or several epidermal growth factor (EGF)-like domains are found. The number of EGF-like domains varies among the matrilins, with four EGF-like domains found in matrilin-3 [6] [7] [8] . A second vWFAlike domain occurs in matrilin-1, -2, and -4, however in matrilin-3 this domain is absent 7, 9 . At the C-terminal end of the molecule, all matrilins carry a coil-coiled -helical domain, responsible for the assembly into oligomeric aggregates (for refs see Deák et al. 5 ). Matrilin-3 is a recently discovered matrilin with a putative function in the assembly of the cartilage extracellular matrix 6, 7 . It is expressed in growing skeletal tissues of man, mouse and chicken 7, 8, 10, 11 . In 6-week-old mice, matrilin-3 mRNA is mainly found in the epiphyseal growth plate and in the bone forming cells 10 . The expression pattern of matrilin-3 in the growth plate is similar to that of matrilin-1 12 . Therefore, expression of matrilin-3 indicates a role in the development of skeletal tissues. However, in normal adult articular cartilage, matrilin-1 expression is very limited or absent 13, 14 . The expression of matrilin-3 in osteoarthritic cartilage has not been previously studied. In the progress of OA, articular cartilage chondrocytes behave similarly to those in the epiphyseal growth plate in that they differentiate, undergo hypertrophy, and, in a further differentiation step, express a posthypertrophic phenotype 15, 16 . We have systematically analysed the expression of matrilin-3 mRNA and protein in normal and osteoarthritic cartilage to define its role in the physiology and pathophysiology of osteoarthritic cartilage. Our results contribute to a better understanding of the complex matrix interactions in OA.
Material and methods

CARTILAGE/BONE SAMPLES
Thirty osteoarthritic cartilage/bone samples were obtained from 17 patients with primary OA (54-to 75 year-old donors) undergoing total knee replacement. Clinical data were carefully reviewed to exclude any forms of secondary OA and inflammatory joint diseases like rheumatoid arthritis. Normal cartilage was collected from five human knees at the time of autopsy within 18 h after death (34-to 56-year-old donors). In these five knees, the femorotibial and patellafemoral joint faces were completely free from any signs of OA. Video printouts were used to document the region where samples were taken. Osteoarthritic changes were classified histomorphologically, using the grading system of Mankin 2 . Mankin score 0: normal cartilage with a smooth surface and a regular zonal distribution of the chondrocytes. Mankin score 1-4: cartilage surface shows fibrillations and a superficial loss of proteoglycans (safranin-O staining); the zonal structure is intact. Mankin score 5-8: Cartilage samples have clefts reaching down to the middle cartilage zone; clusters of proliferating chondrocytes are present. Mankin score ≥9: cartilage samples are severely affected; clefts are reaching down to the deep zone; the tangential zone is lost and chondrocyte clusters are present. Five samples (Mankin score 0), eight samples (Mankin score 1-4), 12 samples (Mankin score 5-8), and 10 samples (Mankin score ≥9) were included in the study. This investigation has been approved by the local ethics commission (application No. 2078).
Cartilage/bone samples of 1 cm thickness with a cartilage surface of about 2.0×0.5 cm were incubated in freshly prepared paraformaldehyde, 4% (w/v), buffered with 0.01 M sodium phosphate, pH 7.4, containing 0.14 M NaCl (PBS) for 12 h at 4°C. The tissue samples were decalcified in diethyl-pyrocarbonate (DEPC)-treated 0.2 M EDTA, pH 8.0, for several weeks at 4°C. The buffer was changed twice a week. Tissue specimens were then dehydrated through graded concentrations of ethanol and xylene and finally embedded in paraffin. Cartilage/bone and cartilage sections (5 m) were mounted on glass slides, precoated with 1% (v/v) 3-aminopropyl triethoxysilane, and heated for 90 min at 65°C.
PREPARATION OF THE MATRILIN-3 RNA PROBE
Total RNA was extracted from human knee cartilage. 0.5 g of cartilage was frozen in liquid nitrogen and pulverized using a stainless steel mortar and pestle. Extraction was performed using cold guanidine isothiocyanate buffer and a subsequent extraction with phenol 17 . 0.5 g of total RNA was transcribed into single-stranded cDNA using AMV reverse transcriptase (Roche, Mannheim, Germany) and Oligo-p(dT)15 as a primer according to the manufacturer's protocol (Roche). Two double-stranded cDNA fragments were generated by PCR using primer pair 1 and 2 ( Table I ). The primer pair 1 spans 785 bases (position 1103-2087) of the coding region of the human matrilin-3 cDNA (Accession No. AJ224741) 8 . The primer pair 2 spans 529 bases (position 238-766) of the coding region of the human matrilin-3 cDNA. After standard PCR (annealing temperature: 60°C, 35 cycles), a T7 promoter-adapter (Ambion, Austin, TX, U.S.A) was ligated non-directionally. The transcription template was performed using a second PCR with the gene-specific forward primer and a T7 promoteradapter primer (Ambion). The amplified PCR products were checked by sequencing (MWG, Ebersberg, Germany).
For in vitro transcription and labeling, 100 ng of the template was transcribed in 1 mM ATP, 1 mM CTP, 1 mM GTP, 0.65 mM UTP and 0.35 mM digoxigenin-11-UTP in 40 mM Tris-HCl, pH 8.0, 6 mM MgCl 2 , 10 mM dithiothreitol, 2 mM spermidine and 40 U T7 RNA-Polymerase (Roche). The components were incubated for 2 h at 37°C. Template DNA was removed with 20 U DNase I (Roche). The reaction was stopped by adding 2 l 0.2 M EDTA pH 8.0. RNA was further purified by ethanol precipitation and resuspended in 100 l DEPC-treated H 2 O. Transcripts were checked for integrity, length, and labeling efficiency by denaturing gel electrophoresis followed by Northern blotting and digoxigenin detection using the DIG-nucleicacid-detection-kit (Roche). For in situ hybridization, approximately 100 ng of matrilin-3 antisense or sense riboprobe were used for each tissue section. Immediately before use, riboprobes were incubated for 10 min at 96°C followed by 2 min at 4°C.
IN SITU HYBRIDIZATION
Tissue sections were deparaffinized in xylene and rehydrated through graded concentrations of ethanol (100% to 50%). Sections were incubated with proteinase K, 50 g/ml in 100 mM Tris, pH 7.5, with 50 mM EDTA, for 15 min at 37°C and postfixed in 4% (w/v) paraformaldehyde/PBS for 1 min. Sections were briefly washed in DEPC-treated double distilled water and acetylated twice for 5 min in 0.1 M triethanolamine by adding 0.3% (v/v) acetic acid anhydride. Sections were briefly incubated in PBS, dehydrated using increasing concentrations of ethanol (50% to 100%), and air-dried under dust-free conditions. Sections were prehybridized with hybridization buffer containing 50% formamide (v/v), 10% dextran (w/v), 0.026% Denhardt's solution (v/v), 0.5 mg/ml fish sperm DNA (Roche), 0.8 M NaCl, 0.6 mM DTT, 0.6 mM EDTA, 7 mM Tris, pH 7.5. They were carefully covered with Parafilm (Sigma, Munich, Germany) and prehybridization carried out for 1 h at 55°C. 50 l of the hybridization solution containing 100 ng of the matrilin-3 probe was applied to each section. The sections were then covered with Parafilm and incubated in a humidified chamber overnight at 55°C. Sense strand in situ hybridization was also performed with the matrilin-3 probes using similar conditions as for the antisense hybridization. After hybridization, the sections were washed with 2×sodium chloride, sodium citrate (SSC), 50% formamide for 30 min at 52°C and with TNE buffer (10 mM Tris, pH 7.5, 0.5 M NaCl, 1 mM EDTA) at 37°C for 10 min. Non-specific binding was abolished by RNase treatment (RNase A, 5 g/ml, in 5 mM Tris, 0.5 M NaCl, pH 7.5, 5 mM EDTA) for 1 h at 37°C. Sections were briefly washed in TNE at 37°C, and then washed in 2×SSC for 20 min at 52°C, and two times in 0.2×SSC for 20 min at 52°C. Detection of bound probes was performed using a commercially available nucleic-acid-detection-kit (Roche). Briefly, sections were incubated in blocking solution containing 10% (v/v) fetal calf serum. After blocking, an antidigoxigenin alkaline phosphatase-labeled antibody was added and bound antibodies were detected after incubation with the substrate solution (X-phosphate/NBT) overnight. Sections were counterstained with 0.5% (w/v) light green (Merck, Darmstadt, Germany) in 5% (v/v) ethanol and mounted in Entellan (Merck).
Nucleic acid sequence homologies were tested using the FASTA program of the EMBL, Heidelberg, Germany. Homologies to listed RNA sequences were less than 55% within an overlapping region of maximal 500 base pairs for the 785 bp probe and less then 60% within an overlapping region of maximal 504 base pairs for the 529 bp probe. The specificity of the probes was controlled by using two different matrilin-3 mRNA probes, which were directed against different portions of the same transcript. Further controls for both matrilin-3 mRNA probes were performed by blocking the signal using unlabeled riboprobes prior the labeled probe. Integrity of the mRNA in cartilage and bone was assessed using a 115 base pair antisense riboprobe for the human 28S RNA (nucleotide 4400-4415, Accession No. M11167, Ambion, Austin, U.S.A.). The hybridization protocol was similar to those used for the matrilin-3 probes, however probe concentration and hybridization temperature was reduced (10 ng per section at 43°C).
IMMUNOLOCALIZATION OF MATRILIN-3
Tissue sections were deparaffinized in xylene and rehydrated. Human cartilage/bone sections were digested with 2 mg/ml hyaluronidase (Merck) in PBS, pH 5.5, for 15 min at 37°C and with 1 mg/ml pronase (Roche) in PBS, pH 7.4, for 30 min at 37°C. After two washes in PBS, sections were incubated in PBS containing 5% (w/v) bovine serum albumin (BSA). The sections were incubated with affinity purified polyclonal antibodies against matrilin-3 in 1% (w/v) BSA/PBS and incubated overnight at 4°C. The specificity of these antibodies has been demonstrated elsewhere 10 . After three washes in tris-buffered saline (TBS), a biotinlabeled donkey anti-rabbit IgG antibody (Dianova, Hamburg, Germany) diluted 1:200 in 1% (w/v) BSA/TBS was added and incubated for 30 min at room temperature. After that, alkaline-phosphatase-labeled streptavidin was added according to the protocol of the manufacturer (Dako, Hamburg, Germany). After three short washes in TBS, bound antibodies were visualized using Fast Red (Sigma) as a color substrate. To exclude non-specific background staining, sections were incubated with affinity purified rabbit IgG (Dako), 1:20 000 in 1% (w/v) BSA/PBS and immunohistochemical detection was performed as described above.
WESTERN BLOT ANALYSIS
Cartilage extracts were obtained from normal (N=4) and osteoarthritic samples (N=6), taken from the femoral condyles of human knee joints. Hyaline cartilage was peeled off from the underlying bone and homogenized at 4°C with an Ultraturrax homogenizer (Jahnke and Kunkel, Germany) in 4 M guanidinium chloride, 50 mM sodium acetate, pH 5.8, containing proteinase inhibitors (10 mM Nethylmaleimide, 10 mM phenyl methane sulfonylfluoride, 10 mM benzamidine hydrochloride). After 48 h of stirring at 4°C the insoluble material was removed by centrifugation at 13,000 g, 4°C, for 1 h. Proteins were separated from proteoglycans using an equilibrium centrifugation in a selfforming cesium chloride gradient. The extract was adjusted to a density of 1.35 mg/ml by the addition of solid cesium chloride. A Kontron swing-out rotor (TST 28.38) equipped with polyallomer thick wall tubes (38.5 ml) was used and centrifugation was done for 70 h (105,000×g; r av = 23.89 cm) at 18°C. The gradient was divided into four equal portions from which the two top fractions were pooled and dialysed twice against 50 mM sodium acetate, pH 5.8, containing proteinase inhibitors (see above) and then against distilled water at 4°C for 12 h. Samples corresponding to 15 g protein were lyophilized and redissolved in 1% SDS/sample buffer without dithiothreitol, denatured at 95°C for 5 min and analysed in a vertical SDS gel electrophoresis unit (Pharmacia, Freiburg, Germany) using a 4-22% gradient polyacrylamide gel in a discontinuous buffer system (0.8 mA/cm 2 ). Proteins were blotted onto a nitrocellulose membrane for 2 h by using a constant current of 100 mA. Blotting efficiency and protein loading were controlled by reversible staining with Ponceau S-Red.
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For immunodetection of matrilin-3, the nitrocellulose membrane was destained with distilled water and incubated in TBS containing 1% non-fat dry milk blocking solution (Roche) for 1 h at room temperature. The polyclonal matrilin-3 antibody was diluted in 0.5% blocking solution and incubated for 2 h at room temperature. The membrane was extensively washed in TBS containing 0.1% Tween (TBST) followed by washing in 0.1% blocking solution. A horseradish peroxidase-conjugated goat antirabbit antibody (Dianova) was used at 1:1000 dilution in 0.5% blocking solution after 30 min of incubation at room temperature and appropriate washing in TBST. Chemiluminescence detection was carried out according to the manufacturer's protocol (Roche). Light emissions were visualized on a light sensitive X-ray film (Roche) after 5 to 10 min exposure time.
QUANTITATIVE DETERMINATION OF MATRILIN-3 mRNA USING COMPETITIVE PCR Total RNA was extracted from human knee cartilage and 100 ng transcribed into cDNA as described above. Competitive quantitative PCR (cq-PCR) was carried out using a modification of the protocol of Riedy et al. 18 and Kö hler et al. 19 Quantification of the matrilin-3 mRNA was based on the competitive amplification of matrilin-3 cDNA and an internal cDNA standard (=competitor) with identical primer binding sites. The competitor was generated by PCR, using final concentrations of 0.2 M of primer #3 and 0.2 M of primer #3′ (Table I ), 1.5 mM MgCl 2 , 10 mM Tris pH 8.3, 50 mM KCl pH 8.3, and 2.5U/100 l Taq DNA Polymerase (Roche). Temperature cycling profile was 94°C for 1 min, 55°C annealing for 1 min and 72°C extension for 2 min. Binding of primer #3′ causes the formation of a loop on the sense strand (Fig. 1) . In the following PCR reaction, the Taq polymerase elongates primer #3′ resulting in a cDNA having a 50 bp deletion within the PCR fragment. 30 l of the PCR reaction mixture was size fractionated on a 2% agarose gel, following staining with ethidium bromide. The 202 bp competitor was excised from the gel and purified (gel extraction kit, Qiagen, Hilden, Germany). The concentration of the competitor was determined by measuring the absorbance of aliquots at 260 nm. After that, defined amounts of competitor were added to each tube at room temperature (0.6, 2.4, 9.8, 39, 156, 625, and 2500 fg), tubes were replaced into the thermal cycler at 72°C and 0.625 U Taq DNA Polymerase (Roche) was added. Incubation was continued for 1 min at 72°to synthesize a double stranded cDNA. PCR was then performed by 28 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s and elongation at 72°C for 60 s, ending with a final incubation at 72°C for 10 min to complete polymerization. 10 l of the PCR product was size fractioned on a 2% agarose gel and visualized using ethidium bromide staining. The gel was recorded by video camera and the intensities of the amplified fragments were calculated using the Scion image software tool (Scion Corporation, Frederick, U.S.A.). To correct for differences in molecular weight, competitor values and matrilin-3 cDNA values were divided by their base pair numbers 20 . The ratio of competitor intensity to matrilin-3 intensity vs the known amount of competitor cDNA was plotted in a log-log scale. At the point where competitor intensity and matrilin-3 intensity are in equivalence [log (ratio)=1], the amount of matrilin-3 cDNA is equal to the known amount of competitor template. Results are expressed in femtogram of matrilin-3 cDNA/ng RNA. For control, amplification was performed using 5 ng of the RNA preparation instead of reversed transcribed cDNA to exclude unspecific amplification of DNA. The grading of the cartilage samples from which mRNA was extracted was done by histomorphological validation of the adjacent areas using the Mankin score.
The specificity of the PCR reaction without competitor was checked by sequencing analyses of the amplified PCR product (results not shown). The number of cycles used in qc-PCR was restricted to the exponential phase of the amplification (28 cycles). The linearity of the qc-PCR was controlled by using increasing amounts of cDNA (0-1000 ng). We compared the matrilin-3 mRNA values obtained from normal cartilage and from cartilage with minor and severe lesions, using a non-parametric statistic test (Mann-Whitney U-test). All data are presented as 
Results
PROTEIN AND mRNA LOCALIZATION OF MATRILIN-3 IN NORMAL AND OSTEOARTHRITIC CARTILAGE/BONE
Normal and osteoarthritic cartilage samples were taken from the load bearing area of femoral condyles. Enzymatic pretreatment of the paraffin embedded tissue with hyaluronidase/pronase enhanced staining intensity for matrilin-3 and was therefore used on all tissue sections processed for immunohistochemistry. In all specimens from both normal and osteoarthritic tissue, matrilin-3 depositions were observed (Fig. 2) . In normal cartilage, several layers can be separated by morphological criteria. The lamina splendens, a thin layer directly facing the articular joint space is followed by the tangential, middle, deep, and calcified cartilage zone. Below, the subchondral bone with the bone trabeculae is found. In sections of normal cartilage [Figs 2(A) and 3(A)] the lamina splendens, the tangential and the upper middle zones were stained. Matrilin-3 staining was diffusely distributed in the cartilage matrix, no cellular staining was detectable. In general, staining intensity was faint. In the lower middle zone, the deep zone, and the calcified zone no matrilin-3 deposition was detectable. In subchondral bone trabeculae and in the osteocytes within newly formed osteoid, matrilin-3 staining was present. In cartilage samples with minor osteoarthritic lesions (Mankin score 1-4) the zonal organization is intact, however, the articular surface is fibrillated, with small clefts reaching down to the tangential zone. In these samples (N=10), matrilin-3 deposition was concentrated in the middle zone with some staining seen also in the upper deep zone [ Fig. 2(B) ]. In bone, cells lining the subchondral bone trabeculae and osteocytes stained positive [ Fig. 6(A) ]. Staining for matrilin-3 in cartilage increased in correlation with the severity of the osteoarthritic lesions. In samples with moderate OA (Mankin score 5-8), the tangential zone is absent. Again, matrilin-3 was most prominent in the middle zone and in the upper deep zone [ Fig. 2(C) ]. In comparison to samples with mild osteoarthritic lesions, the staining intensity increased. In addition to a diffuse interterritorial staining, a strong territorial staining was visible in the middle and upper deep zone [ Fig. 4(A) . The extracellular matrix stained in a diffuse pattern and focally a cellular staining was observed. In general, matrilin-3 deposition within the extracellular cartilage matrix was diminished or absent in the cartilage zone adjacent to the articular joint space, independent of the osteoarthritic defects.
To complement the immunohistochemical results the distribution of matrilin-3 mRNA was determined. Chondrocytes expressing matrilin-3 could be detected in all cartilage samples. In normal cartilage, matrilin-3 mRNA was restricted to chondrocytes of the articular surface and of the upper middle zone [ Fig. 3(B) ] and the signal intensity was low. To exclude degradation and loss of mRNA during decalcification and fixation, samples were incubated with the 28S RNA probe as a positive control [ Fig. 3(D) ]. A negative control with the matrilin-3 sense probe in comparable labeling efficiency as the anti-sense probe failed to detect any hybridization signal [ Fig. 3(C) ]. In normal cartilage/bone sections a signal was detected in all nucleated cells. In cartilage samples showing mild, moderate, or severe osteoarthritic lesions, matrilin-3 mRNA expression correlated with the observed protein deposition and the signal intensity was increased as compared to normal samples. Cartilage with mild or moderate osteoarthritic lesions showed a preferred matrilin-3 mRNA synthesis in the middle cartilage zone. In serial sections of the same region, a distinct matrilin-3 mRNA expression is visible [ Fig. 4(B) ].
In addition to the correlated expression of mRNA and protein, proliferating chondrocytes near the articular joint space showed mRNA expression with no or weak protein deposition [ Fig. 5(B) , arrows].
In bone, matrilin-3 protein deposition was correlated with matrilin-3 gene expression. Bone cells lining the bone trabeculae as well as osteocytes within the new-formed osteoid contained matrilin-3 mRNA [ Figs 6(A), (B) ]. In bone cells, the signal intensity was unchanged between normal and osteoarthritic samples. Tibia samples were also analysed and demonstrated no significant differences in the staining pattern compared to the femoral samples (results not shown). When using a second mRNA probe directed against a different portion of the matrilin-3 transcript, an identical distribution pattern was detected (results not shown). Hybridization of osteoarthritic samples with the sense probe showed no hybridization signal (data not shown).
QUANTITATIVE DETERMINATION OF MATRILIN-3 mRNA IN NORMAL AND OSTEOARTHRITIC CARTILAGE
Quantification of matrilin-3 mRNA in normal and osteoarthritic cartilage was carried out using defined serial dilutions of competitor (0.6 fg to 156 fg). The linearity of the assay was controlled using a constant amount of competitor (156 fg) and increasing amounts of cDNA (10-1000 ng). A linear correlation was obtained between 50 and 500 ng for cDNA from normal cartilage and between 50 and 750 ng for cDNA from osteoarthritic cartilage (results not shown). In five normal samples, a mean value of 0.85 fg/ng mRNA was determined by qc-PCR [ Fig. 7(B) ], while the mean value in chondrocytes from tissue with minor osteoarthritic lesions was 12.9 fg/ng mRNA. In samples with severe osteoarthritic lesions the mean level of matrilin-3 mRNA was 32 fg/ng mRNA. Thus, matrilin-3 mRNA amounts were significantly increased in severely osteoarthritic samples as compared to samples with minor lesions (P=0.0095, Mann-Whitney U-test).
ANALYSIS OF MATRILIN-3 IN NORMAL AND OSTEOARTHRITIC CARTILAGE EXTRACTS BY IMMUNOBLOTS
Purified cartilage extracts were analysed under reducing and non-reducing conditions on a 4-22% SDS-PAGE gel, followed by Western blotting using an affinity purified polyclonal antibody against matrilin-3. Under non-reducing conditions, a complex band pattern was seen in samples from healthy donors as well as in osteoarthritic cartilages [ Fig.  8(C) ]. Higher oligomeric forms migrated above 200 kDa, presumably representing tetrameric and trimeric molecules that in part also contain subunits of matrilin-1 10, [21] [22] [23] . Further, two bands around 60 kDa represent intact and slightly degraded matrilin-3 subunits. Indeed, in matrilin-4 a cleavage site was recently located in the linker between the second vWFA-like domain and the coiled-coil domain 24 . A sequence with homology to that at which matrilin-4 is cleaved is present in matrilin-3 between the fourth EGF-like domain and the coiled coil domain. Under reducing conditions, a single band at around 70 kDa appears that presumably represents both the processed and the unprocessed monomers, which are not resolved under reducing conditions [ Fig. 8(D) ]. The degraded forms of matrilin-3 are 
Discussion
Only limited information has been available on the localization and expression of matrilin-3 in adult human cartilage. Expression has been demonstrated in chondrocytes of the mouse epiphyseal growth plate and a function in the skeletal development has been proposed 10 . Proteins with a restricted expression in the growing cartilage of the epiphyseal growth plate characterize certain chondrocyte differentiation stages with a defined phenotype. Interestingly, it has been shown that matrix components of the growth plate are often re-expressed under the pathological conditions in osteoarthritis. This applies not only to type X collagen, alkaline phosphatase, osteocalcin, and osteopontin 15, 16, 25, 26 , but, as we report here, also to matrilin-3. However, matrilin-3 is expressed at low levels also in normal human articular cartilage.
In normal cartilage, matrilin-3 has a restricted deposition within the transition of the superficial layer and the middle cartilage zone. Matrilin-3 expression, as shown by quantitative RT-PCR, in situ hybridization, immunohistochemistry and immunoblots, correlates with the progression of cartilage degeneration. Interestingly, matrilin-3 deposition is not limited to a certain zone in cartilage, but it is restricted within a defined distance of about 100 to 200 m from the articular joint space (Fig. 2) . The staining pattern we observe is pericellular, indicating a function of matrilin-3 in preserving the pericellular environment. Also, type VI collagen is preferentially deposited in the pericellular capsule and the pericellular matrix and is therefore thought to be involved in protective structures serving to withstand the mechanical forces of the extracellular cartilage matrix 27 . On the structural level, both, matrilin-3 and type VI collagen contain vWFA-like domains. Members of the vWFA-domain superfamily have different functions in cell differentiation, cell migration, cell adhesion, hemostasis, and immune response, but share common characteristics in their participation in cell-cell and cell-matrix interactions (reviewed in Colombatti and Bonaldo 28 ). In analogy to type VI collagen, matrilin-3 has been shown to be deposited in pericellular meshworks around rat chondrosarcoma cells and in mouse sternal and tracheal cartilages 10 . Matrilin-3 or matrilin-3 containing filaments may be anchored via interactions with cells or with extracellular components. The interactions of matrilin- 3 have not yet been studied, but the structurally related matrilin-1 has been shown to bind to 1 1 integrin 29 as well as to cartilage proteoglycans 30, 31 , type II collagen 32 , and itself 22 . Our results show a low but significant expression of matrilin-3 mRNA in normal human cartilage, which is highly upregulated in osteoarthritic cartilage. For matrilin-1, a low or minimal expression has been observed in normal human articular cartilage using immunohistochemical methods 13, 14 . In OA, matrilin-1 deposition increases and the immunohistological staining is more pronouncedly cellular and pericellular, with low or absent staining of the interterritorial matrix 14 . Together with our data on matrilin-3 deposition and synthesis, a coexpression of matrilin-1 and matrilin-3 in hetero-oligomers in the cellular environment is likely and may indeed be due to the two types of matrilin subunits occurring in hybrid oligomers 10, [21] [22] [23] or in hybrid filaments.
Data on the functional role of matrilin-3 in cartilage are limited but from deletion analysis in cell culture, there is evidence that vWFA-like domains enables interactions with cellular or extracellular components 10, 21, 22 . So far, no binding partners for matrilin-3 have been identified in vivo except the formation of matrilin-3 homomers and heteromers with matrilin-1 10, 21, 22 . Through expression analysis in developing mouse joints, matrilin-3 was shown to be an integral component of developing cartilage. In the growth plate, expression was observed in the resting cartilage zone as well as in the proliferating and hypertrophic zones, implicating that matrilin-3 participates in cartilage development. In contrast, in mouse articular cartilage matrilin-3 is present in lower amounts and deposit only at the periphery of the joints. This is in agreement with our results showing low expression in the superficial cartilage zone of normal human articular cartilage. In OA, along with an enhanced disintegration of the cellular microenvironment matrilin-3 is gradually lost from the territorial matrix. This indicates that the structural organization is destroyed and a pericellular anchoring of matrilin-3 is reduced. This may in part be due to an increased proteolysis of matrilin-3 in osteoarthritic cartilage. In parallel, there is an increase in matrilin-3 synthesis. Chondrocyte maturation and hypertrophy during development is regulated by factors such as Indian hedgehog protein, PTH-related peptide, the group of bone morphogenic proteins and members of the fibroblast growth factor family. There is evidence, that these proteins influence the differentiation and hypertrophy of chondrocytes also in osteoarthritis and therefore may contribute to matrilin-3 up-regulation. In comparison to the strict regulation of cellular differentiation and activation during embryonal development, the chondrocyte biosynthetic activity in OA is unbalanced, resulting in a matrix which is unable to withstand the physiological mechanical forces.
The low expression of matrilin-3 in normal cartilage and the correlation of tissue damage with the induction of matrilin-3 expression shows that matrilin-3 may be used as a marker for the progression of OA. Studies on the function of matrilin-3 in cartilage as well as the determination of matrilin-3 in body fluids would be helpful in understanding and monitoring the disease process of OA.
